Amphastar Pharmaceuticals delivered a quieter-than-expected second quarter on August 7, 2026, with the headline revenue and earnings growth understating what is actually a margin story unfolding beneath the surface. The franchise's flagship intranasal glucagon product BAQSIMI, the asset that has driven the company for years, is now showing flat-to-down revenue as a generic glucagon competitor begins to encroach, and the management response is to invest aggressively in the biosimilar insulin pipeline to fill the gap. The recent close near the lower end of the 52-week range tells the equity story in one line, with the stock down sharply from its 2025 high and trading at a steep discount to where the franchise sat when BAQSIMI was compounding at double-digit rates.
The thesis for the next four quarters is that 2026 is a transition year, not a deteriorating one, and the equity is paying for the patent-cliff overhang on BAQSIMI before the insulin biosimilar and other pipeline assets can prove they can replace it. The first half showed the franchise still generating strong operating cash flow, up sharply from a year ago, even as net income compressed sharply on a non-cash mark-to-market swing on the interest-rate hedge. The single most important number for the next twelve months is the trajectory of BAQSIMI revenue in the back half and the rate at which the new ipratropium bromide launch ramps. If BAQSIMI stabilizes near its current quarterly run-rate, the equity re-rates as the franchise proves it can self-fund the biosimilar capital program; if the glucagon erosion accelerates, the multiple compresses further toward the bottom of the historical multiple range.
The load-bearing risk is the convertible-notes overhang, with $345.0 million of 2.0% convertible senior notes due March 2029 at a conversion price well above the current trading level, meaning the convertible is functioning as a low-coupon debt instrument rather than equity dilution. The 2026 effective tax rate in the first half rose from the year-ago level, a near-term headwind that needs to normalize for the earnings power to re-emerge. The falsifiable clock is the third-quarter print in early November, which is expected to show whether the gross margin compression in the second quarter is a one-quarter blip or the start of a structural margin reset as the glucagon erosion accelerates.